射频消融与手术治双侧多灶T1N0M0甲状腺乳头状癌长期结局比较
回顾性队列纳入125例双侧多灶(≤3)T1N0M0甲状腺乳头状癌患者(射频消融55例、全甲状腺切除70例)。射频消融在住院时间、手术时间、出血量、费用、并发症率和生活质量评分上均有显著优势。
要点
- 射频消融组肿瘤进展率7.3%,全甲状腺切除组2.9%,但检验效能仅16%。
- 射频消融显著缩短住院时间(0天vs7天)和手术时间(16.5min vs 90min)。
- 射频消融并发症率0%低于全甲状腺切除25.7%,费用更低且生活质量更优。
核心结论
- 对选择性的双侧多灶(≤3)T1N0M0甲状腺乳头状癌患者,射频消融可能是创伤小、费用低、并发症少且生活质量更优的微创选择。
研究设计与样本
- 回顾性队列研究,连续纳入2018年6月至2020年8月治疗的125例双侧多灶(≤3)T1N0M0甲状腺乳头状癌患者。
- 射频消融组55例,全甲状腺切除组70例;全甲状腺切除组均行预防性中央颈淋巴结清扫。
主要发现
- 射频消融组平均随访69.3±6.9个月、全甲状腺切除组66.8±7.9个月后,肿瘤进展率分别为7.3%和2.9%。
- 研究检测复发差异的检验效能严重不足(16%)。
- 射频消融组住院时间0天vs 7天(P< .001)、手术时间16.5 min vs 90 min(P< .001)、术中出血量0 vs 20 mL(P< .001)。
- 射频消融组手术费用¥15,877.1 vs ¥5,065.4(P< .001)、并发症率0% vs 25.7%(P< .001)、生活质量评分13.1 vs 14.8(P< .001)。
- 未从优势病灶的临床或超声特征中发现肿瘤进展的显著预测因素。
临床怎么用
- 对符合条件的双侧多灶(≤3)T1N0M0甲状腺乳头状癌患者,射频消融可作为兼顾微创与生活质量的备选方案。
- 决策时需注意本研究检验效能不足以排除复发差异,应个体化评估并告知长期肿瘤学不确定性。
局限性
- 回顾性设计且样本量有限,检测复发差异的检验效能仅16%。
- 随访时间约5至6年,长期肿瘤学结局仍需更长时间验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study compared long-term outcomes of ultrasound-guided radiofrequency ablation versus total thyroidectomy for bilateral multifocal (≤3) T1N0M0 papillary thyroid carcinoma. METHODS: In this retrospective cohort study, 125 patients with bilateral multifocal T1N0M0 papillary thyroid carcinoma treated between June 2018 and August 2020 were consecutively included. Among them, 55 underwent radiofrequency ablation and 70 underwent total thyroidectomy. All patients underwent total thyroidectomy with prophylactic central neck dissection. Outcomes included tumor progression, complications, costs, and quality of life. RESULTS: After a mean follow-up of 69.3 ± 6.9 months in the radiofrequency ablation group and 66.8 ± 7.9 months in the total thyroidectomy group, the tumor progression rates of the 2 groups were 7.3% and 2.9%, and the study was severely underpowered (16%) to detect a difference in recurrence. Compared with the total thyroidectomy group, the radiofrequency ablation group demonstrated significant advantages in hospital stay (0 day vs 7 days, P< .001), procedure time (16.5 min vs 90 min; P< .001), intraoperative blood loss (0 vs 20 mL; P< .001), procedure cost (¥15,877.1 vs ¥5,065.4; P< .001), complication rate (0% vs 25.7%; P< .001), and quality-of-life scores (13.1 vs 14.8; P< .001). No significant predictors of tumor progression were identified from the clinical or sonographic characteristics of the dominant lesions. CONCLUSION: For selected patients with bilateral multifocal (≤3) T1N0M0 papillary thyroid carcinoma, radiofrequency ablation appears to be a promising minimally invasive option, associated with less trauma, lower cost, fewer complications, and better life quality.
引用
- Sun H, Li S, Mao Y, et al. Long-term outcomes of radiofrequency ablation versus surgery for bilateral multifocal (≤3) T1N0M0 papillary thyroid carcinoma: A retrospective cohort study. Surgery. 2026. PMID: 42102536. doi:10.1016/j.surg.2026.110247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。